Avion Wealth’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Avion Wealth’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25	Closed	-$2K	–	1691
2025 Q1	$2K	Hold	25	–	–	﹤0.01%	789
2024 Q4	$2K	Buy	25 +6	+32%	+$493	﹤0.01%	786
2024 Q3	$1K	Hold	19	–	–	﹤0.01%	942
2024 Q2	$1K	Hold	19	–	–	﹤0.01%	853
2024 Q1	$2K	Hold	19	–	–	﹤0.01%	810
2023 Q4	$1K	Buy	+19	New	+$1.09K	﹤0.01%	1043

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Avion Wealth's ITCI Position: Q2 2025 in Review

Avion Wealth sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 25 shares — an estimated $2K sold.

Avion Wealth first reported a position in ITCI in Q4 2023 and held it in 6 quarters. The position peaked at $2K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Avion Wealth reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Avion Wealth sold 25 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2K.
Avion Wealth first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 6 quarters.
Avion Wealth's Intra-Cellular Therapies Inc. position peaked at $2K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Avion Wealth's 13F filing for Q2 2025, filed 25 Jul 2025.